A randomized, open-label, multicenter trial to determine safety and efficacy of eculizumab in the prevention of antibody mediated rejection (AMR) in living donor kidney transplant recipients requiring desensitization therapy

Protocol: 
AAAI8755

A randomized, open-label, multicenter trial to determine safety and efficacy of eculizumab in the prevention of antibody mediated rejection (AMR) in living donor kidney transplant recipients requiring desensitization therapy

The purpose of the study is to determine if eculizumab is safe and could be used following desensitization therapy to prevent a condition called antibody mediated rejection (AMR).

Closed to patient enrollment.

Specialty Area(s)

Trial Location

United States